Intuitive Surgical, Inc. $ISRG Shares Sold by ABN Amro Investment Solutions

ABN Amro Investment Solutions lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 49.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 9,727 shares of the medical equipment provider’s stock after selling 9,336 shares during the period. ABN Amro Investment Solutions’ holdings in Intuitive Surgical were worth $4,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in Intuitive Surgical by 2.1% during the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after buying an additional 670,302 shares during the period. State Street Corp boosted its holdings in shares of Intuitive Surgical by 1.2% in the second quarter. State Street Corp now owns 15,552,203 shares of the medical equipment provider’s stock valued at $8,451,223,000 after acquiring an additional 182,871 shares during the period. Geode Capital Management LLC grew its position in shares of Intuitive Surgical by 1.4% during the second quarter. Geode Capital Management LLC now owns 8,188,685 shares of the medical equipment provider’s stock worth $4,429,590,000 after acquiring an additional 109,904 shares during the last quarter. Norges Bank acquired a new position in shares of Intuitive Surgical in the 2nd quarter valued at $2,569,260,000. Finally, Invesco Ltd. increased its holdings in shares of Intuitive Surgical by 4.8% in the 2nd quarter. Invesco Ltd. now owns 4,421,133 shares of the medical equipment provider’s stock valued at $2,402,488,000 after acquiring an additional 201,159 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $485.84 on Monday. The business’s fifty day moving average price is $541.62 and its 200 day moving average price is $510.40. The firm has a market capitalization of $172.54 billion, a PE ratio of 61.58, a P/E/G ratio of 3.76 and a beta of 1.65. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $609.08.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The company had revenue of $2.87 billion during the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter last year, the company earned $2.21 earnings per share. Intuitive Surgical’s quarterly revenue was up 18.8% compared to the same quarter last year. Equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ISRG shares. TD Cowen upgraded shares of Intuitive Surgical to a “strong-buy” rating in a research note on Tuesday, January 27th. Truist Financial increased their target price on shares of Intuitive Surgical from $620.00 to $650.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Raymond James Financial raised their price target on Intuitive Surgical from $603.00 to $615.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. UBS Group restated a “neutral” rating on shares of Intuitive Surgical in a research report on Thursday, January 15th. Finally, Evercore decreased their price objective on Intuitive Surgical from $580.00 to $550.00 and set an “in-line” rating for the company in a research report on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $617.23.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 421 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $494.96, for a total transaction of $208,378.16. Following the transaction, the executive vice president directly owned 409 shares in the company, valued at approximately $202,438.64. This represents a 50.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Fredrik Widman sold 133 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $494.96, for a total transaction of $65,829.68. Following the sale, the vice president owned 660 shares of the company’s stock, valued at approximately $326,673.60. The trade was a 16.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 56,189 shares of company stock worth $30,785,441 over the last three months. 0.70% of the stock is currently owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.